Avidity Biosciences, Inc

Avidity Biosciences — Merger or Acquisition (October 2025)

28 slides from Avidity Biosciences's merger presentation, Oct 27, 2025

  1. Slide 1: Novartis Enters into Agreement to Acquire Avidity

    Novartis Enters into Agreement to Acquire Avidity 27 October 2025

  2. Slide 2: Cautionary Statement Regarding Forward-Looking Statements

    Disclaimer Acquisition of Avidity | 27 October 2025 2 Cautionary Statement Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be

  3. Slide 3: Additional Information and Where to Find It

    Disclaimer Additional information and Where to Find It In connection with the spin-off and the merger (the “Transactions”), Novartis, Avidity and SpinCo intend to file relevant documents with the Securities and Exchange Commission (the “SEC”), including a preliminary and definitive proxy statement t

  4. Slide 4: Transaction summary

    Transaction summary Acquisition of Avidity | 27 October 2025 4 DM1 = Myotonic Dystrophy Type 1. FSHD = Facioscapulohumeral Muscular Dystrophy. DMD = Duchenne Muscular Dystrophy. Overview of transaction terms Acquired by Novartis Del-desiran (DM1) Del-zota (DMD44) Del-brax (FSHD) Preclinical neuromus

  5. Slide 5: Agenda

    Agenda Acquisition of Avidity | 27 October 2025 5 Strategic rationale Avidity core value drivers Closing

  6. Slide 6: Strong strategic fit for Novartis

    Strong strategic fit for Novartis Strengthens Neuroscience franchise Adds three late-stage neuromuscular programs, building on Zolgensma experience in SMA Adds first-in-disease pipeline Del-desiran and del-brax on track to be first-ever disease-modifying therapies for DM1 and FSHD Advances xRNA stra

  7. Slide 7: Target M&A profile

    Target M&A profile Transaction in line with capital allocation priorities and target M&A profile; builds on recent Neuroscience deals 1. Growing dividend policy in CHF/share Capital allocation priorities Strengthens key therapeutic area and advances xRNA strategy First- or best-in-class profile Attr

  8. Slide 8: Avidity raises Novartis 2024-2029 sales CAGR from +5% to +6%

    Avidity raises Novartis 2024-2029 sales CAGR from +5% to +6%, and bolsters mid-single digit long-term Acquisition of Avidity | 27 October 2025 8 Deal expected to deliver substantial shareholder returns over time Net sales Illustrative, USD billion, % CAGR cc1 • Expected near-term product launches wi

  9. Slide 9: Agenda

    Agenda Acquisition of Avidity | 27 October 2025 9 Strategic rationale Avidity core value drivers Closing

  10. Slide 10: Avidity brings pioneering AOC platform for RNA therapeutics

    Avidity brings pioneering AOCTM platform for RNA therapeutics, with industry-leading delivery of RNA to muscle mAb OLIGO OLIGO mAb Monoclonal antibodies Oligonucleotide therapies Antibody oligonucleotide conjugates (AOC) Combining the specificity of mAbs with the precision of oligonucleotide therapi

  11. Slide 11: Avidity core value drivers

    Avidity core value drivers Select assets patients in the US and Europe ~45-87k patients in the US and Europe patients in the US On track to be 1st approved drug for DM1 (Phase 3 fully enrolled; readout expected 2026) Designed to address underlying cause of myotonic dystrophy by liberating free MBNL

  12. Slide 12: DM1: Rare progressive neuromuscular disorder with no disease-modifying therapies

    DM1: Rare progressive neuromuscular disorder with a poor prognosis and no disease-modifying therapies Underrecognized, progressive and often fatal neuromuscular disease that primarily affects skeletal, cardiac and smooth muscle Increases in severity from generation to generation Significant impact o

  13. Slide 13: Del-desiran is designed to address the underlying cause of DM1

    Del-desiran is designed to address the underlying cause of DM1 Data shown as mean and standard error. Fold change is calculated per subject as post-treatment relative to baseline; *D<0.05 unpaired + test. Wagner, SD, et al. PLOS Genet. 2016;12(9):e1006316. 1. Rasch-built Myotonic Dystrophy Type 1 Ac

  14. Slide 14: Phase 1/2 MARINA study: Del-desiran data in DM1

    Phase 1/2 MARINA study: Del-desiran demonstrated potential to be a transformational therapy for DM1 patients vHOT = video hand opening time | QMT composite = quantitative muscle testing | PPN = percent predicted normal | DM1-Activ = Rasch-built myotonic dystrophy type 1 activity and participation sc

  15. Slide 15: Phase 3 HARBOR study of del-desiran in DM1 fully enrolled

    Phase 3 HARBOR study of del-desiran in DM1 fully enrolled 1. Rasch-built Myotonic Dystrophy Type 1 Activity and Participation Scale, designed to assess activities of daily living in individuals with DM1. 2. Initiating dose of 2 mg/kg of del-desiran. Global pivotal trial • FDA, EMA and other regulato

  16. Slide 16: FSHD: Rare hereditary disorder causing relentless loss of muscle function

    FSHD: Rare hereditary disorder causing relentless loss of muscle function and progressive disability One of the most common forms of muscular dystrophy, causing progressive muscle weakness, pain, fatigue and disability Onset typically occurs in teenage or early adult years, with steady loss of indep

  17. Slide 17: Phase 1/2 FORTITUDE study: Del-brax results

    Phase 1/2 FORTITUDE study: Del-brax improved functional mobility, strength and upper limb function compared to patients treated with placebo 10MWRT = 10-meter walk-run test | TUG = timed up-and-go; maximal effort | QMT = quantitative muscle testing | PPN = percent predicted normal | RWS = reachable

  18. Slide 18: cDUX biomarker as potential accelerated approval endpoint

    Compelling data in FSHD supports cDUX biomarker as a potential accelerated approval endpoint as upside case cDUX, a direct target of DUX4, elevated 6- to 9-fold in people living with FSHD compared to healthy volunteers Elevated cDUX levels linked to worsening disease and muscle weakness Significant

  19. Slide 19: Phase 3 FORTITUDE-3 study of del-brax in FSHD underway

    Phase 3 FORTITUDE-3 study of del-brax in FSHD underway 1. Final hierarchy will be selected prior to data base lock, based on evaluation of latest natural history data and efficacy data from FORTITUDE biomarker cohort; currently, QMT is assigned as the primary endpoint. Global pivotal trial • Intende

  20. Slide 20: DMD: Severe, early-onset disease with reduced life expectancy

    DMD: Severe, early-onset disease marked by progressive muscle damage and reduced life expectancy Monogenic, X-linked (primarily affecting males), recessive condition characterized by progressive muscle damage and weakness Symptom onset and diagnosis by 4 years of age; leads to loss of ambulation by

  21. Slide 21: Phase 1/2 EXPLORE44 study: Del-zota results

    Phase 1/2 EXPLORE44 study: Del-zota showed improvements across key biomarkers and functional endpoints, with favorable safety and tolerability Note: In EXPLORE44, most common TEAEs occurring in ≥3 participants in the del-zota arms include procedural pain and headache. Increase in dystrophin Reductio

  22. Slide 22: Novartis has the commercial capabilities and neuromuscular experience

    Novartis has the commercial capabilities and neuromuscular experience to maximize all three near-term launches 1. Top 3 deciles, based on diagnosed patients. 2. SMA Prescribers: HCPs with at least one patient for Zolgensma and competitors (Spinraza, Evrysdi) since 2017. Source: Compile Claims, Compi

  23. Slide 23: External forecasts indicate multi-billion-dollar peak sales potential

    External forecasts indicate multi-billion-dollar peak sales potential in DM1 and FSHD US LOE not before 2042, not subject to IRA EU LOE not before 2044 US LOE not before 2043, not subject to IRA EU LOE not before 2044 0 1’000 2’000 3’000 4’000 5’000 6’000 7’000 ’25E ’26E ’27E ’28E ’29E ’30E ’31E ’32

  24. Slide 24: Agenda

    Agenda Acquisition of Avidity | 27 October 2025 24 Strategic rationale Avidity core value drivers Closing

  25. Slide 25: Financial highlights

    Financial highlights Capital allocation priorities • Transaction fits with capital allocation priorities and target M&A profile • No change to Novartis’ capital allocation strategy post-close Acquisition of Avidity | 27 October 2025 25 Deal value • Multi-billion-dollar peak sales opportunities in DM

  26. Slide 26: Novartis News social post on Avidity acquisition

    rT Novartis News @ 2 @NovartisNews Novartis has entered into an agreement to acquire Avidity, a San Diego- based, publicly traded biopharmaceutical company, committed to delivering a new class of therapeutics enabling RNA delivery to muscle called Antibody Oligonucleotide Conjugates (AOCs™) for seri

  27. Slide 27: Additional information and Where to Find It

    Additional information and Where to Find It In connection with the spin-off or sale of SpinCo and the merger (the “Transactions”), Novartis, Avidity and SpinCo intend to file relevant documents with the Securities and Exchange Commission (the “SEC”), including a preliminary and definitive proxy stat

  28. Slide 28: Press article: Novartis agrees to buy Avidity Biosciences

    Talks between Novartis and Avidity were first reported by the FT in August © Bloomberg Hannah Kuchler in London and Oliver Barnes in Los Angeles Published AN HOUR AGO | Updated 13:35 Novartis has agreed to buy Avidity Biosciences, a biotech focused on rare diseases, for $12bn, in the biggest acquisi

Avidity Biosciences — Merger or Acquisition (October 2025) on 6ix